Original article by Stephen Cauchi
The Australian Financial Review – Page: 31 : 13-Apr-15

Shares in biotechnology group CSL reached a record $A95.43 on 20 March 2015, prompting speculation that the stock could rise above $A100. A full-year profit downgrade saw the stock fall to $A83 in February, but it has since rebounded to $A95.11 on 10 April. Credit Suisse has upgraded its share price target from $A88 to $A106 in recent weeks, while UBS, Macquarie Group and Goldman Sachs also expect the stock to top $A100

CORPORATES
CSL LIMITED – ASX CSLCREDIT SUISSE (AUSTRALIA) LIMITEDUBS HOLDINGS PTY LTDMACQUARIE GROUP LIMITED – ASX MQGGOLDMAN SACHS AND PARTNERS AUSTRALIA PTY LTDWILSON HTM INVESTMENT GROUP LIMITED – ASX WIGJP MORGAN AUSTRALIA LIMITEDCOMMONWEALTH BANK OF AUSTRALIA – ASX CBAMORNINGSTAR PTY LTDBBY LIMITEDRIO TINTO LIMITED – ASX RIOCSL BEHRING